SCHEDULE: Oramed Executive Nadav Kidron Boosts Stake to 7.6%

Nadav Kidron, a key figure at Oramed Pharmaceuticals Inc., has increased his beneficial ownership to 7.6% of the company's common stock, primarily through equity grants.

Summary

• Nadav Kidron, the reporting person, beneficially owns 3,116,729 shares of Oramed Pharmaceuticals Inc. common stock, representing approximately 7.6% of the outstanding shares.
• This ownership includes 1,998,335 directly acquired shares, 762,750 shares from exercisable stock options, 63,541 RSUs vesting within 60 days, 73,500 vested but unissued RSUs, and 218,603 shares held by Xiaopeng Li with shared voting power.
• Since the original Schedule 13D filing on March 22, 2024, Mr. Kidron was granted 45,000 RSUs (vested November 7, 2024), 433,500 RSUs (granted January 2, 2025, vesting quarterly, with 108,375 vested by August 1, 2025), and 186,000 Performance Stock Units (PSUs) (granted January 2, 2025, vested February 11, 2025).
• Additionally, 141,000 PSUs granted on January 4, 2024, and 100,000 PSUs granted on February 3, 2021, also vested on February 11, 2025, based on the achievement of applicable performance criteria.
• The beneficial ownership calculation is based on 41,003,600 shares of common stock outstanding as of August 12, 2025.

Sentiment

Score: 7

Explanation: The increase in Nadav Kidron's beneficial ownership, largely driven by the vesting of performance-based equity awards (PSUs) and the granting of new RSUs, indicates successful achievement of internal performance criteria and continued alignment of a key executive's interests with the company's long-term success. This is generally viewed as a positive, albeit expected, development.

Positives

• Increased beneficial ownership by Nadav Kidron to 7.6% of Oramed Pharmaceuticals Inc. common stock, indicating strong insider alignment.
• Significant vesting of Performance Stock Units (PSUs) on February 11, 2025, totaling 427,000 units (186,000 + 141,000 + 100,000), based on the achievement of applicable performance criteria.
• Granting of additional Restricted Stock Units (RSUs), including 45,000 immediately vested units and 433,500 units with a three-year vesting schedule, further aligning management interests with shareholders.

Future Outlook

No specific forward-looking statements or guidance are provided in this beneficial ownership amendment.

Industry Context

This filing is a routine update on beneficial ownership by a key executive and does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Increased alignment of a key executive's interests with shareholder value through higher beneficial ownership, potentially signaling confidence in the company's future.
• Employees: The vesting of performance-based units for a key executive may reinforce the company's compensation structure and performance incentives.

Next Steps

• Continued quarterly vesting of the 433,500 RSUs granted on January 2, 2025, over a three-year period.
• Potential future exercise of 762,750 stock options exercisable within 60 days of February 11, 2025.
• Issuance of 73,500 vested but not yet issued RSUs.

Key Dates

Recommendation

The filing provides an update on Nadav Kidron's beneficial ownership, showing an increase primarily from the vesting of equity compensation awards. While increased insider ownership is generally a positive indicator of alignment, this is an expected outcome of executive compensation plans rather than a new, strategic investment. The information does not fundamentally alter the company's risk profile, financial outlook, or competitive position. Therefore, a 'hold' recommendation is appropriate, as there is no new information compelling a change in investment stance based solely on this filing.

Keywords

Oramed Pharmaceuticals, Nadav Kidron, Schedule 13D, beneficial ownership, common stock, equity grants, RSUs, PSUs